Waters Corporation (WAT) exhibits 59.3% gross margins and 16.8% return on invested capital within Health Care (Biotechnology: Laboratory Analytical Instruments), balanced against a 51.5x enterprise multiple and 4.8% implied options volatility.
Sustained 59.3% gross profitability converts into 25.4% operating margin and 16.8% ROIC, outpacing sector cost of capital.
ROIC: 16.8% // GM: 59.3%YoY revenue trajectory of +7.0% paired with 1.08% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +7.0% // FCF YLD: 1.08%Altman Z-Score of 15.49 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.
ALTMAN Z: 15.49 // F-SCORE: 9/9Trading at 73.4x trailing P/E (68.3x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 73.4x // EV/EBITDA: 51.5xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $449.53 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Laboratory Analytical Instruments require continuous execution to defend 20.3% net margins.
NET MARGIN: 20.3% // D/E: 0.37x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for WAT & activate live FRED threshold breach alerts.